Document Detail

Endothelial reconstitution by CD34+ progenitors derived from baboon embryonic stem cells.
MedLine Citation:
PMID:  23301772     Owner:  NLM     Status:  MEDLINE    
In this study, we used a large non-human primate model, the baboon, to establish a step-wise protocol to generate CD34+ endothelial progenitor cells (EPCs) from embryonic stem cells (ESCs) and to demonstrate their reparative effects. Baboon ESCs were sequentially differentiated from embryoid body cultures for 9 days and then were specified into EPCs by culturing them in monolayer for 12 days. The resulting EPCs expressed CD34, CXCR4 and UEA-1, but neither CD31 nor CD117. The EPCs were able to form intact lumen structures when seeded on Matrigel, took up Dil-LDL, and responded to TNF-α. Angioblasts specified in EGM-2 medium and ECGS medium had 6.41 ± 1.16% (n = 3) and 9.32 ± 3.73% CD34+ cells (n = 3). The efficiency of generating CD34+ EPCs did not differ significantly from ECGS to EGM-2 culture media, however, angioblasts specified in ECGS medium expressed a higher percentage of CD34+/CXCR4+ cells (3.49 ± 1.32%, n = 3) than those specified in EGM-2 medium (0.49 ± 0.52%, n = 3). To observe their reparative capacity, we purified CD34+ progenitors after specification by EGM-2 medium; inoculated fluorescently labelled CD34+ EPCs into an arterial segment denuded of endothelium in an ex vivo system. After 14 days of ex vivo culture, the grafted cells had attached and integrated to the denuded surface; in addition, they had matured further and expressed terminally differentiated endothelial markers including CD31 and CD146. In conclusion, we have proved that specified CD34+ EPCs are promising therapeutic agents for repairing damaged vasculature.
Qiang Shi; Gerald Schatten; Vida Hodara; Calvin Simerly; John L VandeBerg
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2013-01-10
Journal Detail:
Title:  Journal of cellular and molecular medicine     Volume:  17     ISSN:  1582-4934     ISO Abbreviation:  J. Cell. Mol. Med.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-02-27     Completed Date:  2013-11-19     Revised Date:  2014-02-04    
Medline Journal Info:
Nlm Unique ID:  101083777     Medline TA:  J Cell Mol Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  242-51     Citation Subset:  IM    
Copyright Information:
© 2013 The Authors. Published by Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD34 / metabolism*
Blotting, Western
Cell Differentiation*
Cell Proliferation
Cells, Cultured
Embryonic Stem Cells / cytology*,  drug effects,  metabolism
Endothelium, Vascular / cytology*,  drug effects,  metabolism
Flow Cytometry
Fluorescent Antibody Technique
Neovascularization, Physiologic*
Stem Cells / cytology*,  drug effects,  metabolism
Tumor Necrosis Factor-alpha / pharmacology
Grant Support
C06 RR015456/RR/NCRR NIH HHS; P01 HL028972/HL/NHLBI NIH HHS; P01 HL028972/HL/NHLBI NIH HHS; P51 OD011133/OD/NIH HHS; P51 OD011133/OD/NIH HHS; P51 RR013986/RR/NCRR NIH HHS
Reg. No./Substance:
0/Antigens, CD34; 0/Tumor Necrosis Factor-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Solubility advantage from amorphous etoricoxib solid dispersions.
Next Document:  Reduction of Belt Restraint Use: Long-Term Effects of the EXBELT Intervention.